Tectonic Therapeutic

Update in progress

TECX (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Tectonic Therapeutic, Inc. is a biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G protein–coupled receptors (GPCRs). It uses its GEODe platform to enable GPCR-targeted biologics. Its lead product, TX45, is an Fc-relaxin fusion that activates the RXFP1 receptor. The company is also developing TX2100 for hereditary hemorrhagic telangiectasia, a GPCR modulator bispecific for fibrosis, and other GPCR programs. Based in Watertown, Massachusetts.

Company score

Sentiment: 0.12; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.00; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.06; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive